A Trial of Napabucasin (BBI-608) Plus Weekly Nab-paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Key Inclusion Criteria
- Age ≥18 years
- ECOG PS 0 or 1
- Life expectancy >12 weeks
- Histologically or cytologically confirmed metastatic PDAC
- Not received chemotherapy or any investigational agent for the treatment of PDAC
- Nab-paclitaxel with gemcitabine therapy is appropriate for the patient and recommended by the Investigator
See www.clinicaltrials.gov for comprehensive eligibility criteria.
Global sites in Asia, North America, and Europe, including Japan and the US, are actively recruiting. Please check www.clinicaltrials.gov for updates about this study (NCT02993731) and for a listing of clinical study site locations.
Napabucasin is an investigational, orally administered agent hypothesized to inhibit cancer stemness pathways, and has not yet been approved by the FDA or any other health authorities.
IV=intravenously; RECIST 1.1=Response Evaluation Criteria in Solid Tumors version 1.1; ECOG PS=Eastern Cooperative Oncology Group Performance Status.